[logo] HealthTree Foundation
search person

Clinical Trial: Selinexor in Heavily Pretreated Myeloma Patients

Posted: Oct 21, 2016
Clinical Trial: Selinexor in Heavily Pretreated Myeloma Patients image

A new drug called Selinexor is now being tested in clinical trials for heavily pretreated multiple myeloma patients. Patients who were previously exposed to IMiDs (immunomodulators like lenalidomide or pomalidomide) or proteasome inhibitors (bortezomib, cartilzomib) and have been refractory to both an IMiD and proteasome inhibitor can join this trial. Refractory means that patients have stopped responding to a particular drug. This Phase II trial uses both selinexor and low-dose dexamethasone twice weekly and is open in 25 site locations. To learn more about this clinical trial, click here: Selinexor Clinical Trial Note: Our Myeloma Crowd Radio show on October 28th will cover this new drug. 

A new drug called Selinexor is now being tested in clinical trials for heavily pretreated multiple myeloma patients. Patients who were previously exposed to IMiDs (immunomodulators like lenalidomide or pomalidomide) or proteasome inhibitors (bortezomib, cartilzomib) and have been refractory to both an IMiD and proteasome inhibitor can join this trial. Refractory means that patients have stopped responding to a particular drug. This Phase II trial uses both selinexor and low-dose dexamethasone twice weekly and is open in 25 site locations. To learn more about this clinical trial, click here: Selinexor Clinical Trial Note: Our Myeloma Crowd Radio show on October 28th will cover this new drug. 

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can contribute to cures by joining HealthTree Cure Hub and joining clinical research. Founder and CEO of HealthTree Foundation. 

newsletter icon

Get the latest thought leadership on your Multiple Myeloma delivered straight to your inbox

Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.

Follow Us

facebook instagram linkedin tiktok youtube